Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2026-07-01 18:49:38 ET · period of report 2026-06-29 · accession 0002083206-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 18:49 | 2026-06-29 | LXEO | Tamayo Louis Edward | CFO | A - Grant | $0.00 | +12.0K | 101.7K | +13% | $0 | |
| 2026-07-01 18:49 | 2026-07-01 | LXEO | Tamayo Louis Edward | CFO | S - Sale | $4.49 | -4,641 | 97.0K | -5% | -$20.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | A | A | 12,000 | $0.00 | 101,665 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-01 | S | D | 4,641 | $4.49 | 97,024 | D | — | — | (F1) Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs"). (F2) This transaction was executed in multiple trades at prices ranging from $4.33 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) Includes 89,665 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. |